Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Adenylate cyclase type 3 (ADCY3)
- Target
- ADCY3
- Molecular classification
- Enzyme, Membrane-associated enzyme, Adenylate cyclase family
01
Overview
Adenylate cyclase type 3 (ADCY3) is a membrane-associated enzyme that catalyzes the conversion of ATP to cyclic adenosine monophosphate (cAMP) in response to G-protein signaling[3]. It is widely expressed in human tissues, especially in primary neuronal cilia and olfactory neuroepithelium, and plays a central role in the regulation of cellular signal transduction, energy metabolism, glucose homeostasis, and neuroendocrine functions[1][3][4]. Genetic variants in ADCY3 are linked to predisposition to obesity, type 2 diabetes, and potentially neuropsychiatric conditions such as major depressive disorder. Recent studies implicate ADCY3 in cancer biology, notably as a tumorigenic factor in gastric cancer via the cAMP/PKA/CREB pathway[2]. Currently, there are no approved drugs that specifically or directly target ADCY3 in clinical use.
- Other names
- AC-IIIAC3BMIQ19KIAA0511ATP pyrophosphate-lyase 3Adenylate cyclase 3Adenylyl cyclase 3Adenylate cyclase, olfactive type
02
Mechanism of action
Catalysis of cAMP production from ATP in response to G-protein signaling, modulation of downstream cAMP/PKA/CREB pathway
03
Biological functions
Signal transductionEnergy metabolism regulationGlucose homeostasiscAMP synthesisNeuroendocrine integrationOlfaction
04
Disease associations
ObesityType 2 diabetesMajor depressive disorderGastric cancerOther metabolic disorders
05
Safety considerations
Modulation could alter metabolic or neuroendocrine balancepotential risks in targeting due to its wide tissue distribution and diverse physiological roleslack of selective inhibitors may pose therapeutic challenges
06
Interacting drugs
None established as of current knowledge for direct, clinically approved interactions
07
Biomarkers
Elevated ADCY3 expression as a potential prognostic marker in gastric cancerpossible biomarker for obesity predisposition
Beyond the preview
Go deeper on Adenylate cyclase type 3 (ADCY3).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Adenylate cyclase type 3 (ADCY3).